Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity

Kroll, Ashley V.; Fang, Ronnie H.; Jiang, Yao; Zhou, Jiarong; Wei, Xiaoli; Yu, Chun Lai; Gao, Jie; Luk, Brian T.; Dehaini, Diana; Gao, Weiwei; Zhang, Liangfang

doi:10.1002/adma.201703969

Cited by 410 publications

(319 citation statements)

References 48 publications

(44 reference statements)

Supporting

Mentioning

311

Contrasting

Order By: Relevance

“…Similar to subunit nanovaccines, several groups have co‐encapsulated lysates of dissected tumor tissues and TLR agonists in particulate nanosystems to activate immune cells against cancer . Cancer‐derived membranes and CpG have been coloaded into PLGA nanoparticles to activate multi‐antigenic immunity and developed a productive approach to expedite endogenous immunity against autologous materials, which coincides with previous experiment results . Intriguingly, Santos and co‐workers assessed the immunostimulative properties of two nanovaccines containing a biological cancer cell membrane and a model antigen, respectively .…”

Section: Nanomaterials For Traditional and Novel Vaccine Deliverysupporting

confidence: 59%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

109

View full text Add to dashboard Cite

Cancer immunotherapy is a promising cancer terminator by directing the patient's own immune system in the fight against this challenging disorder. Despite the monumental therapeutic potential of several immunotherapy strategies in clinical applications, the efficacious responses of a wide range of immunotherapeutic agents are limited in virtue of their inadequate accumulation in the tumor tissue and fatal side effects. In the last decades, increasing evidences disclose that nanotechnology acts as an appealing solution to address these technical barriers via conferring rational physicochemical properties to nanomaterials. In this Review, an imperative emphasis will be drawn from the current understanding of the effect of a nanosystem's structure characteristics (e.g., size, shape, surface charge, elasticity) and its chemical modification on its transport and biodistribution behavior. Subsequently, rapid‐moving advances of nanoparticle‐based cancer immunotherapies are summarized from traditional vaccine strategies to recent novel approaches, including delivery of immunotherapeutics (such as whole cancer cell vaccines, immune checkpoint blockade, and immunogenic cell death) and engineered immune cells, to regulate tumor microenvironment and activate cellular immunity. The future prospects may involve in the rational combination of a few immunotherapies for more efficient cancer inhibition and elimination.

show abstract

Section: Nanomaterials For Traditional and Novel Vaccine Deliverysupporting

confidence: 59%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

109

View full text Add to dashboard Cite

show abstract

“…Encouraged by the outstanding enzyme‐mimicking activity and immune activating properties of Cu 2− x Te NEs, we next evaluated their in vivo antitumor performance in bilateral tumor‐bearing mice. PD‐1 antibody (αPD‐1), as a Food and Drug Administration (FDA) approved checkpoint inhibitor, was used to suppress tumor immune evasion (see Figure S25). Tumor growth was monitored through bioluminescence imaging (see Figure S26).…”

Section: Resultsmentioning

confidence: 99%

Artificial Enzyme Catalyzed Cascade Reactions: Antitumor Immunotherapy Reinforced by NIR‐II Light

et al. 2019

View full text Add to dashboard Cite

Current cancer therapy is seriously challenged by tumor metastasis and recurrence. One promising solution to these problems is to build antitumor immunity. However, immunotherapeutic efficacy is highly impeded by the immunosuppressive state of the tumors. Here a new strategy is presented, catalytic immunotherapy based on artificial enzymes. Cu2−xTe nanoparticles exhibit tunable enzyme‐mimicking activity (including glutathione oxidase and peroxidase) under near‐infrared‐II (NIR‐II) light. The cascade reactions catalyzed by the Cu2−xTe artificial enzyme gradually elevates intratumor oxidative stress to induce immunogenic cell death. Meanwhile, the continuously generated oxidative stress by the Cu2−xTe artificial enzyme reverses the immunosuppressive tumor microenvironment, and boosts antitumor immune responses to eradicate both primary and distant metastatic tumors. Moreover, immunological memory effect is successfully acquired after treatment with the Cu2−xTe artificial enzyme to suppress tumor relapse.

show abstract

“…The CCNPs were able to retain several important cancer cell membrane proteins and could effectively mature bone marrow–derived dendritic cells when MPLA was incorporated into the cell membrane coating. This work was further developed by using a CpG‐loaded double emulsion nanoparticle as the core, which was coated in a similar manner with B16F10 cancer cell membrane ( Figure ) . The CpG was chosen to take advantage of the fact that nanoparticles are generally taken up by dendritic cells into the endosomal compartment, where the adjuvant can then be released to interact with its receptor TLR9.…”

Section: Biomimetic Anticancer Nanovaccinesmentioning

confidence: 99%

Section: Biomimetic Anticancer Nanovaccinesmentioning

confidence: 99%

Biomimetic Nanotechnology toward Personalized Vaccines

et al. 2019

Self Cite

View full text Add to dashboard Cite

While traditional approaches for disease management in the era of modern medicine have saved countless lives and enhanced patient well‐being, it is clear that there is significant room to improve upon the current status quo. For infectious diseases, the steady rise of antibiotic resistance has resulted in super pathogens that do not respond to most approved drugs. In the field of cancer treatment, the idea of a cure‐all silver bullet has long been abandoned. As a result of the challenges facing current treatment and prevention paradigms in the clinic, there is an increasing push for personalized therapeutics, where plans for medical care are established on a patient‐by‐patient basis. Along these lines, vaccines, both against bacteria and tumors, are a clinical modality that could benefit significantly from personalization. Effective vaccination strategies could help to address many challenging disease conditions, but current vaccines are limited by factors such as a lack of potency and antigenic breadth. Recently, researchers have turned toward the use of biomimetic nanotechnology as a means of addressing these hurdles. Recent progress in the development of biomimetic nanovaccines for antibacterial and anticancer applications is discussed, with an emphasis on their potential for personalized medicine.

show abstract

Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity

Cited by 410 publications

References 48 publications

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Artificial Enzyme Catalyzed Cascade Reactions: Antitumor Immunotherapy Reinforced by NIR‐II Light

Biomimetic Nanotechnology toward Personalized Vaccines

Contact Info

Product

Resources

About